A company focused on developing targeted therapies for hematologic cancers, particularly myeloproliferative neoplasms (MPNs), using computational chemistry and structural biology to create therapies for unmet medical needs.

Ajax Therapeutics

EcoR1 Capital

Boxer Capital

NYU Langone Health

Inning One Ventures

Schrödinger

Memorial Sloan - Kettering Cancer Center

Ajax Therapeutics Announces FDA Clearance of IND Application for AJ1-11095, a First-in-Class Type II JAK2 inhibitor, for the Treatment of Myelofibrosis

https://lnkd.in/gcC35a5E

Next stop->clinic for AJ-101095! (please note my COI as co-founder)

Financial Times article today about Ajax Therapeutics $95M Series C raise in support of AJ1-11095 clinical development:  

https://lnkd.in/gMPNt7U3

Ajax Therapeutics Raises $95 Million Series C Financing To Advance First-in-Class Type II JAK2 Inhibitor, AJ1-11095, Into The Clinic

– Financing led by Goldman Sachs Alternatives with participation by new investors Lilly, Vivo Capital, RA Capital Management, Point72 and existing investors – 
– AJ1-11095 will be the first Type II JAK2 Inhibitor to enter the clinic; Phase 1 study in myelofibrosis expected to begin in 2H 2024 –

https://lnkd.in/g5dJfqRM

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Jul 18, 2024 3:28 AM	1c660804
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	Jul 18, 2024 3:28 AM	899b45e4
translate crunchbase fundingrounds	general
peers	general	Jul 18, 2024 3:28 AM	b3e197d5
news basic	general	Jul 18, 2024 3:28 AM	e7f802a1
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

AJAX

COM:AJAXTHERAPEUTICS

Ajax Therapeutics